ALSO NOTED: Zentiva under pressure; New China drug manufacturing pact; Par ships new generic;

> Being sued by Teva over patent rights was bad enough, but Czech drug maker Zentiva is also facing court challenges over a land sale and, separately, debt collection. Meanwhile, its first-half profits are down almost 7 percent from last year because of "pricing pressure." Report

> A British pharmacy chain has inked a deal to manufacture its own prescription drugs. The Co-operative Group's meds will be made in China via a joint venture with Tasly Group, one of that country's largest makers of herbal remedies. Report 

> Par Pharmaceutical has started shipping new 100 mg and 200 mg strengths of its generic form of TOPROL-XL, AstraZeneca's beta-1-selective adrenoceptor blocking agent. Release

And Finally... Say goodbye to the last remaining shred of the Soviet Union's pharmaceuticals industry (such as it was). Its sole remaining drug, ethmozine, a treatment for arrythmia, will no longer be sold. Until now, it's been made by Shire---and it does still work. It's just not much in demand. All together now: Do svidaniya! Report (WSJ sub. req.)

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.